Basel Medical Group Ltd income statement BMGL

Annual Quarterly

In fiscal 2025, which ended Jun 30, 2025, Basel Medical Group Ltd reported revenue of $8.9 million. It recorded a net loss of $8.4 million. Diluted earnings per share were -$0.45.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Jun 30, 2025
Revenue
9
Pretax income
-9
Income tax
-0
Net income
-8
Basic EPS
-0.45
Diluted EPS
-0.45
Weighted average shares, basic
19
Weighted average shares, diluted
19
Margins
Pretax margin
-97.65%
Profit margin
-93.96%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
Listed as
BMGL (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Virgin Islands, British
Headquarters
Singapore, Singapore
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2004489

Other Services-Offices & Clinics of Doctors of Medicine companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.